Technical Analysis for LGVN - Longeveron Inc.

Grade Last Price % Change Price Change
F 6.19 -0.64% -0.04
LGVN closed down 0.64 percent on Friday, July 23, 2021, on 62 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical LGVN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -0.64%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.64%
Inside Day Range Contraction -0.64%
Wide Bands Range Expansion -0.64%
Oversold Stochastic Weakness -0.64%
50 DMA Resistance Bearish -6.35%
Bullish Engulfing Bullish -6.35%
Older End-of-Day Signals for LGVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Reversed from Up 3 days ago
Gap Up Closed 3 days ago
Gapped Up (Partial) 3 days ago
10 DMA Resistance 3 days ago
Down 1% 3 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Longeveron Inc. Description

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.


Classification

Sector: Other
Industry: Other
Keywords: Biotechnology Life Sciences Biology Stem Cells Cell Biology Cell Therapy Mesenchymal Stem Cell Acute Respiratory Distress Syndrome

Is LGVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.48
52 Week Low 5.1512
Average Volume 192,178
200-Day Moving Average 0.00
50-Day Moving Average 6.83
20-Day Moving Average 7.17
10-Day Moving Average 6.50
Average True Range 0.51
ADX 29.5
+DI 18.55
-DI 19.07
Chandelier Exit (Long, 3 ATRs) 6.87
Chandelier Exit (Short, 3 ATRs) 7.55
Upper Bollinger Bands 8.72
Lower Bollinger Band 5.61
Percent B (%b) 0.19
BandWidth 43.40
MACD Line -0.25
MACD Signal Line -0.10
MACD Histogram -0.1543
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.78
Resistance 3 (R3) 6.83 6.68 6.68
Resistance 2 (R2) 6.68 6.53 6.66 6.64
Resistance 1 (R1) 6.44 6.44 6.37 6.39 6.61
Pivot Point 6.29 6.29 6.26 6.27 6.29
Support 1 (S1) 6.05 6.14 5.98 6.00 5.77
Support 2 (S2) 5.90 6.05 5.88 5.74
Support 3 (S3) 5.66 5.90 5.70
Support 4 (S4) 5.61